194 related articles for article (PubMed ID: 37679783)
1. Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies.
Rodriguez I; Kocik-Krol J; Skalniak L; Musielak B; Wisniewska A; Ciesiołkiewicz A; Berlicki Ł; Plewka J; Grudnik P; Stec M; Siedlar M; Holak TA; Magiera-Mularz K
Mol Cancer; 2023 Sep; 22(1):150. PubMed ID: 37679783
[TBL] [Abstract][Full Text] [Related]
2. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis.
Zyla E; Musielak B; Holak TA; Dubin G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443436
[TBL] [Abstract][Full Text] [Related]
5. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).
Shaabani S; Huizinga HPS; Butera R; Kouchi A; Guzik K; Magiera-Mularz K; Holak TA; Dömling A
Expert Opin Ther Pat; 2018 Sep; 28(9):665-678. PubMed ID: 30107136
[TBL] [Abstract][Full Text] [Related]
6. Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.
Magiera-Mularz K; Skalniak L; Zak KM; Musielak B; Rudzinska-Szostak E; Berlicki Ł; Kocik J; Grudnik P; Sala D; Zarganes-Tzitzikas T; Shaabani S; Dömling A; Dubin G; Holak TA
Angew Chem Int Ed Engl; 2017 Oct; 56(44):13732-13735. PubMed ID: 28881104
[TBL] [Abstract][Full Text] [Related]
7. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules.
Yang J; Hu L
Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856
[TBL] [Abstract][Full Text] [Related]
9. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
11. In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors.
Klebansky B; Backer M; Gorbatyuk V; Vinogradova O; Backer J
Biomolecules; 2024 May; 14(5):. PubMed ID: 38786004
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.
Bojko M; Węgrzyn K; Sikorska E; Kocikowski M; Parys M; Battin C; Steinberger P; Kogut MM; Winnicki M; Sieradzan AK; Spodzieja M; Rodziewicz-Motowidło S
Bioorg Chem; 2022 Nov; 128():106047. PubMed ID: 35963023
[TBL] [Abstract][Full Text] [Related]
13. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.
Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M
Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226
[TBL] [Abstract][Full Text] [Related]
14. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.
Kurino T; Matsuda R; Terui A; Suzuki H; Kokubo T; Uehara T; Arano Y; Hisaka A; Hatakeyama H
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041818
[TBL] [Abstract][Full Text] [Related]
15. Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer.
Islam MK; Stanslas J
Pharmacol Ther; 2021 Nov; 227():107870. PubMed ID: 33895183
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold.
Cai S; Wang K; Qi Z; Ye K; Zhou X; Jiang S; Zhang K; Zhang X; Wang T
Eur J Med Chem; 2023 Aug; 256():115468. PubMed ID: 37207535
[TBL] [Abstract][Full Text] [Related]
17. Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019-2021).
Deng J; Cheng Z; Long J; Dömling A; Tortorella M; Wang Y
Expert Opin Ther Pat; 2022 May; 32(5):575-589. PubMed ID: 35272536
[TBL] [Abstract][Full Text] [Related]
18. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Yan Y; Zhang L; Zuo Y; Qian H; Liu C
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
[TBL] [Abstract][Full Text] [Related]
20. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
